FI117508B - Förfarande för framställning av en ligand som binder sig vid CD40CR-receptorn - Google Patents
Förfarande för framställning av en ligand som binder sig vid CD40CR-receptorn Download PDFInfo
- Publication number
- FI117508B FI117508B FI930605A FI930605A FI117508B FI 117508 B FI117508 B FI 117508B FI 930605 A FI930605 A FI 930605A FI 930605 A FI930605 A FI 930605A FI 117508 B FI117508 B FI 117508B
- Authority
- FI
- Finland
- Prior art keywords
- cell
- protein
- cells
- activated
- cd40cr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (8)
1. Förfarande för framställning av en väsentligen renad, cellfri ligand, vilken ligand specifikt binder sig 5 vid CD40CR-receptorn, ett 39 kDa T-cellprotein som binder sig vid CD40-B~cellantigenen och stimulerar inledande, förökning genom celldelning och differentiering av B-cell-cykeln, varvid nämnda ligand: a) omfattar ätminstone en del av den extracellu-10 lära domänen av ett CD40-protein med en i figur 8A med aminosyrorna 1-193 visad sekvens, fäst vid en andra mole-kyl, varvid nämnda andra molekyl valts frän gruppen bestä-ende av peptider, proteiner, kolhydrater och lipider, och väri den extracellulära domänen pä fusionsstället har ami-15 nosyrasekvensen Gly-Pro-Gln-Asp-Pro-Glu, och varvid nämnda ligand - b) förmär binda sig vid nämnda CD40CR-protein i en aktiverad hjälpar-T-cell och inhibera aktiveringen av en vilande B-cell som sker genom inverkan av den aktiverade
20 T-cellen, kännetecknat av att man använder rekombi-nant-DNA-teknik. • t
: 2. Förfarande enligt patentkrav 1, känneteck- • · · ί.,,ϊ n a t av att den andra molekylen är ätminstone en del av : :*: 25 en immunoglobulinmolekyl. * * * :1;
3. Förfarande enligt patentkrav 2, känneteck- * * · nat av att delen av immunoglobulinfragmentet omfattar • · ett Fc- fragment. • · ·
4. Förfarande enligt patentkrav 3, känneteck- , 30 nat av att Fc-fragmentet omfattar ett scharner-, CH2- • · * *|* och CH3-omräde.
* · *·;·* 5. Förfarande enligt patentkrav 1, känneteck- :V: nat av att liganden är CD40-Ig, som producerats med :1· pCD40-lg-plasmiden, som avbildats i figur 8B. * · t .*. 35
6. Förfarande för framställning av ett väsentligen « · *;**, renat, cellfritt CD40/immunoglobulinfusionsprotein, vilket • · · • · * * · 117508 34 fusionsprotein specifikt binder sig vid möss-CD40CR-recep-torn, ett 39 kDa möss-T-cellprotein som binder sig vid CD40-B-cellantigenen och stimulerar inledande, förökning genom celldelning och differentiering av B-cellcykeln, 5 varvid nämnda fusionsprotein omfattar ätminstone en del av CD40-proteinets extracellulära domän med en i figur 8A med aminosyrorna 1-193 visad sekvens, och vari den extracellulära domänen pä. fusionsstället har aminosyrasekvensen Gly-Pro-Gln-Asp-Pro-Glu, kännetecknat av att man använ-10 der rekombinant-DNA-teknik.
7. Förfarande enligt patentkrav 6, kännetecknat av att fusionsproteinet särskilt konkurrenskraftigt inhiberar bindningen av CD40-proteinet vid möss-CD40CR-receptorn. 15
8. Förfarande enligt patentkrav 6, känneteck- ' . .1 n a t av att fusionsproteinet särskilt konkurrenskraftigt * inhiberar bindningen av en monoklonal antikropp, som pro-ducerats med ett hybridom deponerat i American Type Culture Collection -deponeringsinstitutionen med nummer ATCC HB 20 11048, vid dess mälantigen. • a a a a * · · Ml a «·· • · ··· • · · • * · * • · · • · · ® · • · ·*· • · · • · · • · ·«· • · · ·'··'.·· • !·'·.·' /1 • φ · # · # * φ · · # φ φ • φ φ · *·· φ • · Φ φ · • a · • a a a a a φ • a . I • Φ a a i φ a a a a • Φ · aa aa . . a a a a a a • ·
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83579992A | 1992-02-14 | 1992-02-14 | |
US83579992 | 1992-02-14 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI930605A0 FI930605A0 (fi) | 1993-02-11 |
FI930605A FI930605A (fi) | 1993-08-15 |
FI117508B true FI117508B (sv) | 2006-11-15 |
Family
ID=25270498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI930605A FI117508B (sv) | 1992-02-14 | 1993-02-11 | Förfarande för framställning av en ligand som binder sig vid CD40CR-receptorn |
Country Status (16)
Country | Link |
---|---|
US (2) | US6376459B1 (sv) |
EP (2) | EP1489099A3 (sv) |
JP (2) | JP4148537B2 (sv) |
KR (1) | KR100301146B1 (sv) |
AT (1) | ATE273998T1 (sv) |
AU (2) | AU3298893A (sv) |
CA (1) | CA2089229C (sv) |
DE (1) | DE69333591T2 (sv) |
DK (1) | DK0555880T3 (sv) |
ES (1) | ES2225820T3 (sv) |
FI (1) | FI117508B (sv) |
IL (1) | IL104684A0 (sv) |
NO (1) | NO316024B1 (sv) |
NZ (1) | NZ245898A (sv) |
PT (1) | PT555880E (sv) |
ZA (1) | ZA931013B (sv) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
DK0667901T4 (da) * | 1991-10-25 | 2008-11-10 | Immunex Corp | Hidtil ukendt cytokin |
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
WO1994004570A1 (en) * | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
IL110852A (en) * | 1993-09-02 | 1999-05-09 | Dartmouth College | Methods of prolonged suppression of humoral activity |
EP0721346B1 (en) * | 1993-09-02 | 1998-06-10 | Trustees of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
KR100398819B1 (ko) * | 1993-09-02 | 2004-02-05 | 트러스티스 오브 다트마우스 칼리지 | gp39길항제를포함하는약제조성물 |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
AU1059095A (en) * | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
MX9605088A (es) | 1994-04-28 | 1997-08-30 | Boehringer Ingelheim Pharma | Metodos para proliferar y diferenciar celulas b y sus usos. |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US5652224A (en) * | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US6372208B1 (en) | 1999-09-28 | 2002-04-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
WO1996028568A1 (en) | 1995-03-13 | 1996-09-19 | The Regents Of The University Of Michigan | Cd40 binding compositions and methods of using same |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
CA2224812A1 (en) * | 1995-06-22 | 1997-01-09 | Biogen, Inc. | Crystals of fragments of cd40 ligand and their use |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
EP0892643B2 (en) * | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
NZ333602A (en) * | 1996-07-08 | 2000-06-23 | Biogen Inc | Treatment of smooth muscle cell dependent disease using antibodies capable of inhibiting the CD40 - CD40 ligand interaction |
JP2002507967A (ja) * | 1997-06-20 | 2002-03-12 | パンゲネチックス・ベー・ファウ | 疾病治療のための抗cd40lイムノトキシン |
CA2223225A1 (en) * | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
CN100352497C (zh) * | 1998-04-03 | 2007-12-05 | 达特茅斯学院理事 | 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 |
IL130989A0 (en) * | 1999-07-20 | 2001-01-28 | Compugen Ltd | Variants of alternative splicing |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
EP1717251B1 (en) | 2000-10-02 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Therapy for B-cell malignancies using human anti-CD40 antibodies |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
CA2477202A1 (en) * | 2002-02-22 | 2003-08-28 | Compugen Ltd. | Cd40 splice variants, compositions for making and methods of using the same |
US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
AU2003226065B2 (en) | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
CN1897959A (zh) | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
WO2006033702A2 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
EP2422811A2 (en) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
UA97469C2 (uk) * | 2005-07-25 | 2012-02-27 | Емерджент Продакт Дівелопмент Сіетл, Елелсі | Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
US8697846B2 (en) * | 2007-08-15 | 2014-04-15 | Emory University | Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
BRPI0921321A2 (pt) | 2008-11-28 | 2018-10-16 | Emory University | métodos para o tratamento de indwcções e tumores |
SG194561A1 (en) | 2011-04-21 | 2013-12-30 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40 |
US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
KR20190126332A (ko) * | 2017-03-07 | 2019-11-11 | 유니버시타트 바셀 | 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체 |
MA50435A (fr) | 2017-05-24 | 2020-09-02 | Als Therapy Development Inst | Anticorps anti-ligand anti-cd40 thérapeutiques |
TW201900213A (zh) * | 2017-05-27 | 2019-01-01 | 美商免疫醫療公司 | 免疫球蛋白a陽性細胞的調節 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
DE69226871T3 (de) * | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
TR199902191T2 (xx) | 1997-01-10 | 1999-12-21 | Biogen, Inc. | Anti-CD40L bile�ikleri ile lupus nefritis tedavisi |
AU5623398A (en) | 1997-03-07 | 1998-09-22 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
WO1999000143A1 (en) | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
-
1993
- 1993-02-10 IL IL104684A patent/IL104684A0/xx not_active IP Right Cessation
- 1993-02-10 CA CA2089229A patent/CA2089229C/en not_active Expired - Fee Related
- 1993-02-11 FI FI930605A patent/FI117508B/sv not_active IP Right Cessation
- 1993-02-12 DK DK93102279T patent/DK0555880T3/da active
- 1993-02-12 PT PT93102279T patent/PT555880E/pt unknown
- 1993-02-12 NO NO19930521A patent/NO316024B1/no not_active IP Right Cessation
- 1993-02-12 ES ES93102279T patent/ES2225820T3/es not_active Expired - Lifetime
- 1993-02-12 EP EP04012091A patent/EP1489099A3/en not_active Withdrawn
- 1993-02-12 ZA ZA931013A patent/ZA931013B/xx unknown
- 1993-02-12 EP EP93102279A patent/EP0555880B1/en not_active Revoked
- 1993-02-12 AT AT93102279T patent/ATE273998T1/de active
- 1993-02-12 NZ NZ245898A patent/NZ245898A/en not_active IP Right Cessation
- 1993-02-12 AU AU32988/93A patent/AU3298893A/en not_active Abandoned
- 1993-02-12 DE DE69333591T patent/DE69333591T2/de not_active Expired - Lifetime
- 1993-02-13 KR KR1019930002045A patent/KR100301146B1/ko not_active IP Right Cessation
- 1993-02-15 JP JP02553093A patent/JP4148537B2/ja not_active Expired - Lifetime
- 1993-08-31 US US08/114,944 patent/US6376459B1/en not_active Expired - Lifetime
-
1996
- 1996-11-26 AU AU71980/96A patent/AU701306B2/en not_active Expired
-
2003
- 2003-10-16 JP JP2003356578A patent/JP3984944B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-10 US US11/127,046 patent/US7445781B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE273998T1 (de) | 2004-09-15 |
NZ245898A (en) | 1995-04-27 |
KR100301146B1 (ko) | 2001-10-22 |
JP4148537B2 (ja) | 2008-09-10 |
US6376459B1 (en) | 2002-04-23 |
EP0555880A3 (en) | 1994-05-11 |
CA2089229A1 (en) | 1993-08-15 |
DK0555880T3 (da) | 2004-12-06 |
AU3298893A (en) | 1993-08-19 |
FI930605A (fi) | 1993-08-15 |
CA2089229C (en) | 2010-04-13 |
DE69333591T2 (de) | 2005-09-01 |
MX9300768A (es) | 1997-09-30 |
DE69333591D1 (de) | 2004-09-23 |
AU7198096A (en) | 1997-02-06 |
JP2004115527A (ja) | 2004-04-15 |
NO316024B1 (no) | 2003-12-01 |
KR930017919A (ko) | 1993-09-20 |
IL104684A0 (en) | 1993-06-10 |
ZA931013B (en) | 1993-09-20 |
NO930521D0 (no) | 1993-02-12 |
EP0555880B1 (en) | 2004-08-18 |
EP1489099A3 (en) | 2008-02-20 |
JP3984944B2 (ja) | 2007-10-03 |
PT555880E (pt) | 2004-12-31 |
US7445781B2 (en) | 2008-11-04 |
FI930605A0 (fi) | 1993-02-11 |
JPH06220096A (ja) | 1994-08-09 |
NO930521L (no) | 1993-08-16 |
ES2225820T3 (es) | 2005-03-16 |
US20060008460A1 (en) | 2006-01-12 |
EP0555880A2 (en) | 1993-08-18 |
EP1489099A2 (en) | 2004-12-22 |
AU701306B2 (en) | 1999-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI117508B (sv) | Förfarande för framställning av en ligand som binder sig vid CD40CR-receptorn | |
US10934353B2 (en) | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use | |
EP0842948B1 (en) | ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME | |
CA2563313C (en) | Modulation of nkg2d | |
US5948893A (en) | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody | |
BRPI0620141B1 (pt) | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, inibidor para a atividade de uma célula produtora de interferon, reagente para detecção de célula produtora de interferon, método de detecção de célula produtora de interferon, método in vitro de inibição da atividade de uma célula produtora de interferon, hibridoma, método de produção de um anticorpo monoclonal, polinucleotídeo isolado e vetor | |
US6472510B1 (en) | CD40 receptor ligands | |
AU734853B2 (en) | Methods of prolonged suppression of humoral immunity | |
JPH07242566A (ja) | 免疫抑制剤 | |
AU743824B2 (en) | Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease | |
Dehghanpisheh et al. | Retrovirally induced mouse anti‐TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens | |
US20020058037A1 (en) | Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease | |
Morita et al. | Arsonate-specific murine T cell clones. III. Correlation between clonotype expression and fine specificity for analogs of L-tyrosine-p-azobenzenearsonate. | |
MXPA93000768A (en) | Cd40cr receptor and ligands therefor | |
del Guercio et al. | Inhibitory activity of interleukin B on the suppressor T cell hybrid T2D4. | |
Arendt | Physical and functional interactions of the hematopoietic cell-specific protein-tyrosine phosphatase CD45 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 117508 Country of ref document: FI |
|
MA | Patent expired |